Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jviscsurg.2020.04.013 http://scihub22266oqcxt.onion/10.1016/j.jviscsurg.2020.04.013 32387058!7177076!32387058     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Visc+Surg 2020 ; 157 (3S1): S25-S31 Nephropedia Template TP {{tp|p=32387058|t=2020. Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic Proposals for prioritization from the RENAPE and BIG-RENAPE groups |pdf=|usr=}}{{32387058}} gab.com Text Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic Proposals for prioritization from the RENAPE and BIG-RENAPE groups JO: J Visc Surg http://www.kidney.de/pget.php?&tw=1&pmid=32387058 #FOAvip The Covid-19 pandemic is profoundly changing the organization of healthcare access. This is particularly so for peritoneal neoplastic diseases, for which curative treatment mobilizes substantial personnel, operating room and intensive care resources. The BIG-RENAPE and RENAPE groups have made tentative proposals for prioritizing care provision. A tightening of the usual selection criteria is needed for curative care: young patients with few or no comorbidities and limited peritoneal extension. It is desirable to prioritize disease conditions for which cytoreduction surgery with or without associated hyperthermic intraoperative peritoneal chemotherapy (HIPEC) is the gold-standard treatment, and for which systemic chemotherapy cannot be a temporary or long-term alternative: pseudomyxoma peritonei, resectable malignant peritoneal mesotheliomas, peritoneal metastases of colorectal origin if they are resectable and unresponsive to systemic chemotherapy after up to 12 courses, first-line ovarian carcinomatosis if resectable or in interval surgery after at most six courses of systemic chemotherapy. Addition of HIPEC must be discussed case by case in an expert center. The prioritization of indications must consider local conditions and the phase of the epidemic to allow optimal peri-operative care. Twit Text FOAVip Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic Proposals for prioritization from the RENAPE and BIG-RENAPE groups ????J Visc Surg http://www.kidney.de/pget.php?&tw=1&pmid=32387058 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32387058 #FOAvip English Wikipedia <ref>{{Cite pmid|32387058}}</ref> Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic Proposals for prioritization from the RENAPE and BIG-RENAPE groups #MMPMID32387058 Glehen O; Kepenekian V; Bouche O; Gladieff L; Honore C J Visc Surg 2020[Jun]; 157 (3S1): S25-S31 PMID32387058show ga The Covid-19 pandemic is profoundly changing the organization of healthcare access. This is particularly so for peritoneal neoplastic diseases, for which curative treatment mobilizes substantial personnel, operating room and intensive care resources. The BIG-RENAPE and RENAPE groups have made tentative proposals for prioritizing care provision. A tightening of the usual selection criteria is needed for curative care: young patients with few or no comorbidities and limited peritoneal extension. It is desirable to prioritize disease conditions for which cytoreduction surgery with or without associated hyperthermic intraoperative peritoneal chemotherapy (HIPEC) is the gold-standard treatment, and for which systemic chemotherapy cannot be a temporary or long-term alternative: pseudomyxoma peritonei, resectable malignant peritoneal mesotheliomas, peritoneal metastases of colorectal origin if they are resectable and unresponsive to systemic chemotherapy after up to 12 courses, first-line ovarian carcinomatosis if resectable or in interval surgery after at most six courses of systemic chemotherapy. Addition of HIPEC must be discussed case by case in an expert center. The prioritization of indications must consider local conditions and the phase of the epidemic to allow optimal peri-operative care. |*Coronavirus Infections[MESH] |*Pandemics[MESH] |*Pneumonia, Viral[MESH] |COVID-19[MESH] |Health Priorities/*organization & administration[MESH] |Humans[MESH]Treatment of primary and metastatic peritoneal tumors in the Covid-19 (epmc).pdf DeepDyve Pubget Overpricing